Skip to content

Licéno

Active
Private limited company·Activiteiten van huisartspraktijken· 2 yrs active
François Demarsinstraat 21 ·3012 Leuven, Belgium
KBO/BCE: BE 1000.811.653
Watch Print / PDF
Age2 yrs

Summary

Conclusion

the dossier summarised in one paragraph

The computed 12-month bankruptcy probability of Licéno is 0.2% (very low). The 2025 annual accounts show equity of €27k and a net result of €6k. Equity is growing by ~60% per year across the filed fiscal years. Its solvency ranks better than 58% of 2207 sector peers (fiscal year 2025). The company has been active since 2023 and the Belgian State Gazette contains no insolvency or warning signals.

Based on the State Gazette, CBE and 3 annual accounts.

Signals

2 signals · with evidence
Consistently profitable
Positive net result in the two most recent financial years (2024 and 2025).
View the result trend
Growing equity
Equity grew over 2023-2025. Profits are largely retained rather than distributed.
View the equity trend

Signals are derived from the filed annual accounts and the sector comparison. No composite score: each signal is separately verifiable at the source.

Trust signals

3 signals
Young company
Founded in 2023, under 3 years, statistically higher risk.
No legal incidents
No bankruptcy, reorganisation or interim measure in the Belgisch Staatsblad.
Administratively compliant
No FOD Economie strikeouts (UBO, accounts, address, activity).

Administrative Flags

0 events
No administrative flags

Bankruptcy probability (12 mo)

Checked model v1 · free for everyone
0.2% Very low
0%0,5%1,5%4%10%≥25%
Lower-failure-rate sector Young company +Annual accounts: healthy financial profile

Statistical estimate based on public sources, not credit advice nor a finding of fact. How do we compute this?

Financials

TurnoverNot published (abbreviated filing)
EBIT marginNot published (abbreviated filing)
Net result€6k-66.4%
Working capital€4k

Annual accounts & ratios

Source: NBB · 2025
Annual accounts filed on 02-04-2026 with the NBB · fiscal year 2025 · micro
€0€10k€20kOperating result 2023: €3k€3kNet result 2023: €2k€2kOperating result 2024: €23k€23kNet result 2024: €19k€19kOperating result 2025: €9k€9kNet result 2025: €6k€6k202320242025
Operating resultNet result
Trajectory (indicative)
Projection over 3 fiscal years from the filed annual accounts, not a forecast, the extended trend.
growing Gross margin: growth of ~40.6%/year over 3 fiscal years, indicative, assuming unchanged policy.
€0€20k€40k2026: €27k (€25k - €28k)2027: €34k (€33k - €36k)2028: €42k (€41k - €44k)2023: €4k2024: €25k2025: €19k202320242025202620272028
Solid line = filed figures · dashed = extended trend · area = indicative range.
How do we compute this?

The trend is a robust median of all pairwise slopes between fiscal years (Theil-Sen), so a single odd year cannot hijack the line. For strictly positive series we also fit a log variant (compound annual growth) and keep whichever describes the figures best.

The area around the projection is 1.8 × the median absolute deviation from the trend, widening each year ahead (×1 / ×1.6 / ×2.2), with a minimum of 8% of the last value. It is an indicative range, not a statistical confidence interval.

A series whose deviations exceed 35% of its level is too volatile: we then deliberately show no projection. Every projection assumes unchanged policy and is blind to non-public information (order book, contracts, funding rounds).

Sector comparison
Fiscal year 2025 · NACE 86, Human health · compared within the same schema type (micro schema)
Metric This company Sector median Position in the sector
Solvency 67.7% 58.2%
better than 58% of 2207 sector peers
Net result €6k €60k
better than 11% of 2205 sector peers
Equity €27k €74k
better than 31% of 2207 sector peers
Gross operating margin €19k €96k
better than 10% of 2207 sector peers
Total assets €40k €187k
better than 8% of 2207 sector peers
Median and position computed from NBB annual accounts filed by sector peers; own figures from the latest filed accounts.
Sector position over time
Percentile per fiscal year versus peers that filed figures, computed year by year (a year without enough peers is absent).
Solvency P58
2023: P33 · n=53262024: P40 · n=65692025: P58 · n=22072023 2025
Improving position over 2023-2025 · n=2207-6569
Net result P11
2023: P12 · n=53252024: P27 · n=65632025: P11 · n=22052023 2025
Stable position over 2023-2025 · n=2205-6563
Equity P31
2023: P7 · n=53282024: P19 · n=65692025: P31 · n=22072023 2025
Improving position over 2023-2025 · n=2207-6569
Gross operating margin P10
2023: P6 · n=53222024: P17 · n=65712025: P10 · n=22072023 2025
Stable position over 2023-2025 · n=2207-6571
Describes the position versus peers, not a forecast.
EBITDA
€18k
-26.5% -75% vs sector
Net profit
€6k
-66.4% -87% vs sector
Cash flow
€15k
-24.4% -75% vs sector
Total assets
€40k
+9.6% -88% vs sector
Equity
€27k
+30.2% -90% vs sector
Working capital
€4k
- -98% vs sector
Income taxes
€3k
-35.9% -69% vs sector
Debt
€13k
-17.7% -61% vs sector
Debt ≤ 1y
€11k
-29.6% -67% vs sector
Current ratio
1.40
+541.9% -78% vs sector
Quick ratio
1.40
+541.9% -78% vs sector
Solvency
67.7%
+18.8% -25% vs sector
Debt / equity
0.48
-36.8% far above sector median
ROE
23.2%
-74.2% +53% vs sector
ROA
15.7%
-69.3% +10% vs sector
Interest coverage
387.88
- far above sector median
Figures by fiscal year
Fiscal year2025
Revenue-
EBITDA€18k
Net profit€6k
Cash flow€15k
Staff costs-
Income taxes€3k
Dividends-
Total assets€40k
Equity€27k
Debt€13k
of which ≤ 1y€11k
of which > 1y-
Working capital€4k
Employees (FTE)-
Ratios (computed)
2025
Current ratio1.40
Quick ratio1.40
Working capital ratio11.0%
Solvency67.7%
Debt / equity0.48
Long-term debt ratio-
Interest coverage387.88
Gross margin-
Net margin-
ROA15.7%
ROE23.2%
EBITDA margin-
Days sales outstanding-
Days payable outstanding-
Inventory turnover-
Days inventory (DSI)-
Balance-sheet composition 2025
Full annual accounts
Filed balance sheet and income statement, exactly as deposited with the NBB.
Line item Code2025
Balance sheet, Assets
TOTAL ASSETS 20/58€40k
Fixed assets 21/28€24k
Tangible fixed assets 22/27€24k
Current assets 29/58€15k
Cash & bank 54/58€12k
Balance sheet, Equity & liabilities
TOTAL EQUITY & LIABILITIES 10/49€40k
Equity 10/15€27k
Contributions / capital 10/11€100
Reserves 13€27k
Amounts payable 17/49€13k
Amounts payable within one year 42/48€11k
Income statement
Gross operating margin 9900€19k
Operating result 9901€9k
Financial income 75€0
Financial charges 65€46
Result before taxes 9903€9k
Income taxes 67/77€3k
Net result for the period 9904€6k
Result to be appropriated 9905€6k
You're seeing the latest fiscal year only. Unlock 2 prior years (figures + ratios) with a paid plan. See plans →
Ratios computed by Checked.

Health barometer

FY 2025 · computed
88 / 100 Excellent
050100

Unlock the full score breakdown, per-year score history and the indicative credit limit with Plus.

See plans →
Computed by Checked from NBB filings and Belgian State Gazette signals. Indicative, not credit advice.

Structure & network

Locations & real estate

Establishment units

1 location
François Demarsinstraat 21, 3012 Leuven
Activiteiten van huisartspraktijken
since 20232.350.933.174
Physical sites registered in the Crossroads Bank for Enterprises (CBE).
Parcels1
Ground area962 m²
Buildings1
Building footprint340 m²
Volume (LiDAR)1,728 m³
Tallest building9.2 m · ±2 fl.

Real-estate footprint

Source: CBE × cadastre · address linking

Parcels linked to this company through its CBE addresses (seat, establishment units, branches), cross-referenced with the cadastral parcel plan. This shows where the company operates, not a deeds register.

Flanders 1 (100%)
Parcel (capakey) Region Area Buildings Height / fl.
24126D0012/00P000 Flanders 962 m² 1 · 339 m² 9.2 m · 2 fl.
Methodology
via registered seat: 1
1 of 1 parcels with an exact address match; the rest are indicative.
Linked through address data, this is not proof of ownership.

Analysis

Snowflake analysis

financial profile on 5 axes
Health88Profitability100Solvency87Growth78Stability82
87 / 100

Exceptional profile, strong across almost every axis.

Health 88
Profitability 100
Solvency 87
Growth 78
Stability 82

Ask AI about this company

Checked AI

Soon: ask questions about this dossier, risks, curator, sector comparison, answered from the official data on this page.

TryWhat are the main risks?Any recent red flags?Compare to sector peers
Coming soon

AI due-diligence brief

Checked AI

Generate a structured, factual brief from every signal in this dossier: risk, financial health, ownership, mandates and sector comparison.

Coming soon
AI-generated from Checked data; indicative, not legal or investment advice.

Credit advice

verdict per customer and amount

Should this customer buy amount X on invoice? Enter the amount and payment terms, you get an instant GREEN/AMBER/RED verdict, with a suggested ceiling and concrete conditions.

Based on official sources (NBB, CBE, State Gazette). Indicative, not credit advice.

Similar

Similar companies

Same sector, ranked by comparable size

Company registry

Company registry (CBE)

Crossroads Bank
Activities
Huisartspraktijken86210Activiteiten van huisartspraktijken86210Verhuur en lease van medisch en paramedisch materieel77225Verhuur en lease van medisch en paramedisch materieel77295Verhuur en lease van kantoormachines, inclusief computers77330Verhuur en lease van kantoormachines, inclusief computers77330Overige menselijke gezondheidszorg, n.e.g.86909Activiteiten op het gebied van voeding86995
Primary activity highlighted.
Names & trade names
Legal nameNL Licéno
Registered office
François Demarsinstraat 21
3012 Leuven, Belgium
Official data from the Crossroads Bank for Enterprises (CBE). Available for every registered company.